This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEWARK, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the
6th Neurodegenerative Conditions Research and Development conference. Mr. McGlynn is scheduled to speak at 11:35 a.m. Pacific Time on Friday, September 14. The
Neurodegenerative Conditions Research and Development session is part of the
2nd CNS Diseases World Summit which will be held September 13-14 at the Hilton San Francisco Financial District hotel in downtown San Francisco.
CNS Diseases World Summit brings together leading experts across industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics, and CNS partnering and deal-making. The
Neurodegenerative Conditions track brings together leading scientists and experts to discuss latest breakthroughs, new drug targets, new models, the development of new biomarkers, imaging modalities, and several other novel developments and therapeutics to combat neurodegenerative conditions.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at
The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Rodney Young
Chief Financial Officer